M
Mary Griffin
Researcher at Avon and Wiltshire Mental Health Partnership NHS Trust
Publications - 3
Citations - 741
Mary Griffin is an academic researcher from Avon and Wiltshire Mental Health Partnership NHS Trust. The author has contributed to research in topics: Donepezil & Minimal clinically important difference. The author has an hindex of 3, co-authored 3 publications receiving 674 citations. Previous affiliations of Mary Griffin include King's College London.
Papers
More filters
Journal ArticleDOI
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Robert Howard,Rupert McShane,James Lindesay,Craig W. Ritchie,Ashley Baldwin,Robert Barber,Alistair Burns,Tom Dening,David Findlay,Clive Holmes,Alan Hughes,Robin Jacoby,Robert G. Jones,Roy W. Jones,Ian G. McKeith,Ajay Macharouthu,John T. O'Brien,Peter Passmore,Bart Sheehan,Edmund Juszczak,Cornelius Katona,Robert Kerrin Hills,Martin Knapp,Clive Ballard,Richard G. Brown,Sube Banerjee,Caroline Onions,Mary Griffin,Jessica Adams,Richard Gray,Tony Johnson,Peter Bentham,Patrick P. J. Phillips +32 more
TL;DR: In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months.
Journal ArticleDOI
Determining the minimum clinically important differences for outcomes in the DOMINO trial
Robert Howard,Patrick P. J. Phillips,Tony Johnson,John T. O'Brien,Bart Sheehan,James Lindesay,Peter Bentham,Alistair Burns,Clive Ballard,Clive Holmes,Ian G. McKeith,Robert Barber,Tom Dening,Craig W. Ritchie,Robert Jones,Ashley Baldwin,Peter Passmore,David Findlay,Alan Hughes,Ajay Macharouthu,Ajay Macharouthu,Sube Banerjee,Roy W. Jones,Martin Knapp,Richard G. Brown,Robin Jacoby,Jessica Adams,Mary Griffin,Richard Gray +28 more
TL;DR: Although less likely to be reported in clinical trials than expressions of the statistical significance of differences in outcomes, whether or not a treatment has delivered a specified minimum clinically important difference (MCID) is also relevant to patients and their caregivers and doctors.
Journal ArticleDOI
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
Robert G. Jones,Bart Sheehan,Patrick P. J. Phillips,Ed Juszczak,Jessica Adams,Ashley Baldwin,Clive Ballard,Subrata Banerjee,Bob Barber,Peter Bentham,Richard G. Brown,Alistair Burns,Tom Dening,David Findlay,Richard Gray,Mary Griffin,Clive Holmes,Alan Hughes,Robin Jacoby,Tony Johnson,Roy W. Jones,Martin Knapp,James Lindesay,Ian G. McKeith,Rupert McShane,Ajay Macharouthu,John T. O'Brien,Caroline Onions,Peter Passmore,James Raftery,Craig W. Ritchie,Robert Howard +31 more
TL;DR: The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil, and to provide clear evidence on the best treatment strategies for those managing patients at a particularly important clinical transition point.